Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
TELA Bio (NASDAQ: TELA) reported first quarter 2026 revenue of $19.1 million, up 3% year over year with 13% unit growth. European revenue grew 41%.
Gross margin was 65.7%, net loss was $12.3 million, cash was $39.5 million. Guidance calls for at least 8% 2026 revenue growth and about $20.0 million Q2 revenue.
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants covering 89,250 shares to 12 newly hired employees, with a grant date of May 5, 2026. The RSUs vest in equal annual installments over four years, subject to continued service through each vesting date.
TELA Bio (NASDAQ: TELA) announced a board refresh: four current directors will step down after the 2026 Annual Meeting on June 9, 2026, and four new commercial and finance leaders will join the Board, with Joseph Capper expected to be Chair if elected.
The company reported preliminary Q1 2026 revenue of ~$19.0 million versus prior guidance of ~$18.5 million; final results will be released May 12, 2026.
TELA Bio (NASDAQ: TELA) will report first quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update.
Investors must register online to join the call, registering at least one day in advance or at minimum 15 minutes before the start; a live webcast and replay will be available on TELA's investor Events & Presentations page.
TELA Bio (NASDAQ:TELA) reported Q4 2025 revenue of $20.9M (+18% YoY) and full-year 2025 revenue of $80.3M (+16% YoY). Q4 gross margin improved to 65.9%. Full-year net loss was $38.8M and cash totaled $50.8M. The company closed a $70.0M credit facility (initial $60.0M). Management projects at least 8% revenue growth in 2026 and Q1 2026 revenue of ~$18.5M.
Highlights include expanded commercial field coverage (≈88–89 reps) and promotion of Howard Langstein to Chief Medical Officer.
TELA Bio (NASDAQ: TELA) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update. Investors must register at least one day ahead or 15 minutes before the call. A live webcast and replay will be available on TELA's investor Events & Presentations page.
TELA Bio (NASDAQ: TELA) approved inducement restricted stock unit grants covering 8,550 shares to three newly hired employees, with a grant date of February 18, 2026.
The RSUs vest in equal annual installments over four years and were issued under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation.
TELA Bio (NASDAQ: TELA) announced that its Compensation Committee approved inducement restricted stock unit grants covering 14,250 shares to five newly hired employees with a grant date of January 20, 2026. The awards were made under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation. The restricted stock units will vest in equal annual installments over four years, subject to continued service through each vesting date.
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants to three newly hired employees totaling 3,600 shares, with a grant date of December 9, 2025. The Compensation Committee approved the awards under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation.
The restricted stock units vest in equal annual installments over four years, subject to each employee's continued service through applicable vesting dates.
TELA Bio (NASDAQ: TELA) will present at the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled to present on December 3, 2025 at 2:30 pm ET. Interested parties can access a live and archived webcast at the company's investor site: ir.telabio.com.
The presentation highlights the company’s participation at a major healthcare investor conference and provides a webcast option for remote access.